Dr. Venook Discusses the Results of the 80405 Trial

Alan P. Venook, MD
Published Online: Friday, Aug 15, 2014

Alan P. Venook, MD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses results from the CALGB/SWOG 80405 trial of targeted therapies administered in colorectal cancer.

Venook says this trial took 10 years to complete. This study originally set out to find the best first-line treatment for patients with metastatic colorectal cancer. However, the trial ended up focusing only on patients with wild-type KRAS at codons 12 and 13.

The trial enrolled 1137 patients that were randomized between bevacizumab and cetuximab with chemotherapy, Venook says. The results showed a survival of 29.9 months in the cetuximab arms and 29.0 months in the bevacizumab arms.

Alan P. Venook, MD, professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses results from the CALGB/SWOG 80405 trial of targeted therapies administered in colorectal cancer.

Venook says this trial took 10 years to complete. This study originally set out to find the best first-line treatment for patients with metastatic colorectal cancer. However, the trial ended up focusing only on patients with wild-type KRAS at codons 12 and 13.

The trial enrolled 1137 patients that were randomized between bevacizumab and cetuximab with chemotherapy, Venook says. The results showed a survival of 29.9 months in the cetuximab arms and 29.0 months in the bevacizumab arms.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 12th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 29, 20172.0
Cancer Summaries and Commentaries™: 2016 Conference Coverage: Advances in the Treatment of Genitourinary CancersApr 29, 20172.5
Publication Bottom Border
Border Publication